Text Size
Overview | Description | Applications | Operations | Results | Publications | Images
Experiment/Payload OverviewCommercial Biomedical Testing Module-3: STS-135 space flight's affects on vascular atrophy in the hind limbs of mice (CBTM-3-Vascular Atrophy) examines the effects of space flight on the skeletal bones of mice and the efficacy of a novel agent that may mitigate the loss of bone associated with space flight. Humans and animals have been observed to lose bone mass during the reduced gravity of space flight. CBTM-3-Vascular Atrophy specifically determines if there is a correlation between space flight induced altered blood supply to the bones and surrounding tissues with a resultant loss of bone mass.
Principal Investigator
Payload Developer
Ames Research Center, Moffett Field, CA, United States
National Aeronautics and Space Administration (NASA)
Sponsoring Organization:Information Pending
ISS Expedition Duration:March 2011 - September 2011
27/28
Previous ISS MissionsA similar investigation, CBTM, flew round trip to the ISS on STS-108 during ISS Expedition 4. CBTM-2 flew round trip to the ISS on STS-118 during ISS Expedition 15. AEMs have flown on numerous Space Shuttle missions over the years.
Commercial Biomedical Testing Module-3: STS-135 space flight's affects on vascular atrophy in the hind limbs of mice (CBTM-3-Vascular Atrophy) only receives animals that have not received the therapeutic test agent. Therefore, CBTM-3-Vascular Atrophy compares untreated flight animals with animals that were held in AEM's on the ground during the flight. CBTM-3-Vascular Atrophy focuses on determining whether space flight results in vascular atrophy in the hind limbs leading to a decreased vascular presence and decreased blood supply to the bone and surrounding tissues. CBTM-3-Vascular Atrophy utilizes long bones of the animals provided postflight, specifically a region of the lower hindlimb at mid-calf; a 5-mm long region of interest (ROI) that includes portions of the tibia, fibula and attached skeletal muscles such as the soleus. The rationale for selecting this ROI is that unloading results in sarcopenia and osteopenia (muscle and bone mass loss) in this anatomical region. Samples of tissue are embedded in cryomedium, stained and examined for differences in vascular/blood supply, vessel tissue structure, and decalcification between flight and ground animals. Tissue sections from mouse lower hind limbs are also used to identify potential alterations in vascular cell gene expression as a consequence of space flight. Upon completion of the flight, the research team has access to the mice a few hours after landing.
Nine to ten week old female C57Bl6 mice fly onboard the STS-135 Space Shuttle mission in the CBTM-3 payload. The primary objective of this space mission is to evaluate a sclerostin antibody treatment to promote bone formation and mitigate bone loss in microgravity. This experiment is configured with three animal enclosure modules (AEMs) flown on STS-135 and an additional three AEMs that house ground control mice in the Space Life Sciences Laboratory at Kennedy Space Center. Each AEM contains ten mice.
If a correlation is found between blood supply to bone and bone mass regulation, new insights into the mechanisms governing how the body responds to skeletal unloading will undoubtedly result. Such insights may lead to new therapies for maintaining a healthy musculoskeletal system during long-duration space flights.
Earth ApplicationsAs noted in the preceding paragraph, if a correlation is found between blood supply to bone and bone mass regulation, new insights into the mechanisms governing how the body responds to skeletal unloading will likely result, insights that might lead not only to new therapies for maintaining a healthy musculoskeletal system during long duration space flights, but also new therapies for treating muscle and bone wasting diseases on the Earth.
AEM's with ten mice each are requested for a late load (L-21 hours) and to be removed postflight within four hours of landing. During flight the crew is requested to conduct a daily health check of the animals, i.e., a visual observation through the Lexan lid of the AEMs. Unusual appearance of the animals is to be reported as soon as possible.
Operational ProtocolsFor this study nine to ten week old female C57Bl6 mice are launched on the space shuttle. Flight mice are treated once with a placebo vehicle or therapeutic agent approximately 24 hours before launch. Ground control mice are treated in the same manner but with a 48 hour offset. Ground control mice are housed under the same environmental conditions (temperature, light/dark cycle, humidity, oxygen levels and carbon dioxide levels) as the flight mice. All mice receive the same full access to food and water. Upon return to Earth, the AEMs are returned to the research team for analysis. Body weight is also measured preflight and postflight. Statistical comparisons will be made between the treated and control mice.
Information Pending
NASA Image: JSC2011-E029133 - STS-135 crew members, from the right are NASA astronauts Chris Ferguson, commander; Sandy Magnus and Rex Walheim, both mission specialists, participate in an Animal Enclosure Module (AEM) training session in the Jake Garn Simulation and Training Facility at NASA's Johnson Space Center.